| Labcorp Oncology

May 8, 2023

RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers

Few DNA panels target NRG1 for sequencing. This paper highlights the value of RNA sequencing in OmniSeq for detecting these rare fusions and directing patient treatment.Graphical Summary of RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers

May 2023

Publication

RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers

Eric Severson, B.R. Achyut, Mary Nesline, Sarabjot Pabla, Rebecca A. Previs, Geoffrey Kannan, Anjen Chenn, Shengle Zhang, Roger Klein, Jeffrey Conroy, Mark Sausen, Pratheesh Sathyan, Kamal S. Saini, Aradhana Ghosh, Taylor J. Jensen, Prasanth Reddy, Shakti H. Ramkissoon

View Publication

April 1, 2017

Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient

April 1, 2017

Managing Your Health

Diseases & Therapeutic Areas

Treatment Modalities & Methods

Scientific Lab Disciplines

Labs

Industries

Search Diagnostic Test Menu

RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers

Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient

NGS reveals specimen characteristics have minimal impact on immune gene expression signature

Technical variability in NGS immune gene expression and mutation profiling has a nominal effect on tumor classification

The inflamed phenotype in PD-L1 negative NSCLC and response to checkpoint inhibitors

The inflamed phenotype in PD-L1 negative melanoma and response to checkpoint inhibitors

Algorithmic prediction of response to checkpoint inhibitors

Validation of a custom RNA-Seq approach to cancer immune profiling

An algorithmic approach to cancer immune profiling